前收市價 | 5.37 |
開市 | 5.37 |
買盤 | 5.52 x 100 |
賣出價 | 5.61 x 200 |
今日波幅 | 5.32 - 5.62 |
52 週波幅 | 1.52 - 8.11 |
成交量 | |
平均成交量 | 143,522 |
市值 | 111.472M |
Beta 值 (5 年,每月) | 0.80 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -0.17 |
業績公佈日 | 2024年8月06日 - 2024年8月12日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 7.83 |
Journey Medical (DERM) stock rises as the FDA accepts its regulatory filing for review seeking approval for DFD-29 to treat inflammatory lesions and erythema of rosacea in adults.
When Journey Medical (DERM) reports fourth-quarter 2023 results, investors will likely focus on the top and bottom-line numbers.
Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.